REGENERON PHARMACEUTICALS, INC. (REGN) Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses. Its therapeutic portfolio includes EYLEA, an injection used to treat various ophthalmic conditions such as wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, and macular edema resulting from retinal vein occlusion (both central and branch). Other significant offerings are Dupixent, an injectable solution for atopic dermatitis and asthma in both adults and pediatric patients; Libtayo, indicated for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent, an injection prescribed for adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; REGEN-COV for COVID-19; and Kevzara, a solution targeting rheumatoid arthritis in adult patients. Furthermore, Regeneron provides Inmazeb for infections caused by Zaire ebolavirus; ARCALYST, an injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and Muckle-Wells syndrome; and ZALTRAP, an intravenous infusion used in the treatment of metastatic colorectal cancer. In addition to its existing product lineup, the company is actively engaged in developing novel product candidates aimed at addressing unmet medical needs in areas such as ocular diseases, allergic and inflammatory conditions, cardiovascular and metabolic disorders, infectious diseases, rare diseases, cancer, pain management, and hematologic conditions. Regeneron maintains extensive collaboration and licensing agreements with a diverse range of partners, including Sanofi, Bayer, Teva Pharmaceutical Industries Ltd., Mitsubishi Tanabe Pharma Corporation, Alnylam Pharmaceuticals, Inc., Roche Pharmaceuticals, and Kiniksa Pharmaceuticals, Ltd. It also holds agreements with entities such as the U.S. Department of Health and Human Services, Zai Lab Limited, Intellia Therapeutics, Inc., the Biomedical Advanced Research Development Authority, and AstraZeneca PLC. The company was founded in 1988 and its corporate headquarters are situated in Tarrytown, New York.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Regeneron Pharmaceuticals, Inc. NASDAQ:REGN Healthcare · Biotechnology
Mkt Cap $98.76B
EV -
SI 2.3%
Net Cash/Sh -
Div Yield 0.39%
Prev close $952.40 +0.02%Open $952.56 +0.22%Now $954.65 VOL 358K $ Vol $342.71M RVOL 0.37x
Mkt Cap $98.76B
EV -
VOL 358K sh
$ Vol $342.71M
RVOL 0.37×
SI 2.3%
Net Cash/Sh -
Div Yield 0.39%
Press Release
Libtayo® (cemiplimab) Approved in the European Union (EU) for Extended Dosing and Faster Infusion Times Across Skin, Lung and Cervical Cancer Indications
The European Commission approved a flexible dosing schedule for Regeneron's PD-1 inhibitor Libtayo across all six EU-approved indications in skin, lung and cervical cancers. The approval adds a 700 mg every-six-week maintenance option after 12 weeks of 350 mg every three weeks, and allows infusion times to be cut from 30 minutes to 15 minutes after a well-tolerated first infusion. A U.S.
• 7h ago AI analysis › Press Release
POTS Phase 2 Trial Shows Baloncibart, a First-in-Class NPR1 Blocking Antibody, Reduced Orthostatic Heart Rate and Improved Orthostatic Symptoms
Regeneron announced positive Phase 2 PINNACLE trial results for baloncibart, a first-in-class NPR1-blocking antibody, in postural orthostatic tachycardia syndrome (POTS), a condition with no FDA-approved treatments. A single 450 mg dose reduced the standing heart-rate response versus placebo by an LS mean difference of -11.4 bpm at day 8 (nominal p=0.0007) and -7.4 bpm at day 29, and improved orthostatic symptoms and physical functioning on the LWPQ questionnaire. The 150 mg dose showed a day-8 effect that was not maintained at day 29.
• 4d ago AI analysis › Press Release ● Major
CIDEB siRNA Normalizes Liver Fat and Improves Liver Injury Markers in MASLD Patients, as Highlighted at AASLD
Regeneron reported first-in-human Phase 1/2 results for CIDEB(siRNA) showing a single subcutaneous dose produced 58-80% dose-dependent liver fat reductions sustained through week 36 in MASLD patients. Sixty-two percent of treated patients normalized liver fat at week 36 and 93% achieved reductions of at least 30%, versus a 2.9% mean decrease on placebo; no nausea, vomiting, or discontinuations were seen in treated groups. The data were published in NEJM and presented at AASLD, positioning CIDEB(siRNA) — developed with Alnylam, which receives milestones and royalties — against approved MASH therapies that achieved only 47-57% fat reduction at about one year.
• 8d ago AI analysis › Press Release
Regeneron Announces Investor Conference Presentations
Regeneron announced webcasts of management presentations at three upcoming healthcare investor conferences. The sessions are the Jefferies Global Healthcare Conference in London on November 17, the 9th Annual Evercore Healthcare Conference on December 1, and Citi's 2026 Global Healthcare Conference on December 2.
• 14d ago AI analysis › Press Release ● Critical
Regeneron Reports Third Quarter 2026 Financial and Operating Results
Regeneron posted Q3 2026 revenue of $5.116 billion, up 36% year-over-year, with GAAP EPS of $18.45 (+35%) and non-GAAP EPS of $20.07 (+70%). Dupixent global net sales rose 35% to $6.54 billion and EYLEA HD U.S. sales jumped 62% to $699 million, while legacy EYLEA U.S. sales fell 41% on competition and patient transition to EYLEA HD.
• 18d ago AI analysis › Press Release
Regeneron Extends Agreement with BARDA to Provide Additional Supply of Ebola Treatment Inmazeb® for U.S. Preparedness
Regeneron extended its 2020 procurement agreement with BARDA to supply additional doses of Inmazeb, its FDA-approved Ebola treatment, to the U.S. government through 2031 for approximately $270 million. Separately, Regeneron is adding its investigational maftivimab monotherapy to the WHO-sponsored PARTNERS trial as a potential treatment for Bundibugyo virus, which is driving the current outbreak in the Democratic Republic of the Congo and has no approved treatment options.
• 22d ago AI analysis › Press Release
Libtayo® (cemiplimab) Longer-Term Data Show Increasing and Clinically Meaningful Overall Survival Benefit with Adjuvant Treatment in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC)
globenewswire.com • 23d ago Press Release
Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Updated Dosing Regimen Across All Approved Cancer Types
Regeneron announced that the EMA's CHMP adopted a positive opinion recommending approval of an alternative Libtayo dosing schedule across all approved indications in the EU. The recommended regimen shifts to 700 mg every six weeks after an initial 12 weeks of 350 mg every three weeks, and adds an optional 15-30 minute infusion for the 350 mg dose, cutting treatment time by up to half.
• 1mo ago AI analysis › Press Release
Pasatru™ (garetosmab-grts) Demonstrates Zero New Heterotopic Ossification (HO) Lesions in Adult Fibrodysplasia Ossificans Progressiva (FOP) Patients During OPTIMA Trial Extension
Regeneron's Pasatru showed zero new heterotopic ossification lesions from week 56 to week 84 in the Phase 3 OPTIMA trial versus 9 new lesions for placebo. The 84-week data, presented at ASBMR, showed sustained flare-up reductions (1 flare-up on 10 mg/kg vs 17 for placebo) and a safety profile consistent with the 56-week results.
• 1mo ago AI analysis › Press Release
Regeneron Showcases Advances in Care Across Several Cancers and Cancer-associated Complications at ESMO 2026
Regeneron announced it will present 10 abstracts at the ESMO Congress 2026 (October 23-27, Madrid), spanning CSCC, NSCLC, ovarian cancer, melanoma and cancer-associated thrombosis. Highlights include late-breaking Phase 3 C-POST overall survival data at roughly 3.5 years of follow-up for adjuvant Libtayo in high-risk CSCC, plus the final Phase 2 analysis of neoadjuvant Libtayo and Factor XI antibody (cenvacibart/amrecibart) thrombosis data. No new clinical results were disclosed in this preview; the market-moving readouts will come during the congress sessions themselves.
• 1mo ago AI analysis › Press Release
Ubamatamab (MUC16xCD3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (LGSOC)
Regeneron reported first clinical results for ubamatamab, its MUC16xCD3 bispecific antibody, in recurrent low-grade serous ovarian cancer at the IGCS 2026 meeting. Among 11 heavily pre-treated patients receiving 800 mg monotherapy, ubamatamab showed a 73% objective response rate and 11-month median progression-free survival — well above the sub-15% ORR typical of chemotherapy in this setting, and without biomarker selection. The company is enrolling a dedicated, potentially registrational LGSOC cohort of up to 100 patients at the 800 mg dose, will discuss the data with the FDA in the coming months, and plans a confirmatory randomized Phase 3 trial.
• 1mo ago AI analysis › Press Release
Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss
Regeneron announced Phase 2 COURAGE trial results showing trevogrumab, an anti-myostatin antibody, preserved lean mass during semaglutide-induced weight loss, with findings presented at EASD and accepted by The Lancet. At the lower-dose portion, trevogrumab 75 mg plus semaglutide preserved 50.7% of lean mass at 26 weeks and 42.5% at 52 weeks versus placebo plus semaglutide; MRI substudy data showed roughly 70% of thigh muscle loss was prevented.
• 1mo ago AI analysis › Press Release ● Major
Press Release: Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies
Regeneron and Sanofi expanded their 20-year antibody alliance to co-develop and co-commercialize four new long-acting immunology antibodies targeting IL-13, IL-4xIL-13, IL-4 and IL-4Rα. Regeneron receives a $1 billion upfront payment with up to $7 billion in additional milestones; the companies share development and commercialization costs and split profits 50:50 globally, with Regeneron leading R&D and Sanofi leading commercialization. Lead asset REGN20423, a long-acting IL-13 antibody, is in a phase 1 study for atopic dermatitis, with the other three antibodies expected to enter the clinic in 2027; Regeneron also holds an option to add Sanofi's lunsekimig after its phase 3 COPD studies.
• 1mo ago AI analysis › Press Release ● Major
REG-Press Release: Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies
Regeneron and Sanofi expanded their two-decade global antibody alliance to co-develop and co-commercialize four new long-acting Regeneron-invented immunology antibodies, including phase 1 IL-13 antibody REGN20423. Regeneron will receive $1 billion upfront from Sanofi with potential for up to $7 billion in additional development, regulatory and commercial milestones; profits and costs will be split 50:50 globally, with Regeneron leading R&D and Sanofi leading commercialization. The existing Dupixent profit split is unchanged. The companies also settled their prior collaboration-related litigation, removing an overhang on the partnership.
• 1mo ago AI analysis › Press Release ● Major
Regeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology Antibodies
Regeneron and Sanofi expanded their 20-plus-year antibody alliance, adding four next-generation long-acting antibodies including the Phase 1 IL-13 antibody REGN20423. Regeneron receives $1 billion upfront with up to $7 billion in additional milestones, and the companies will split development costs and future profits 50:50, with Regeneron leading R&D and Sanofi leading commercialization.
• 1mo ago AI analysis › Press Release
Regeneron to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on October 30, 2026
Regeneron announced it will report third quarter 2026 financial and operating results on Friday, October 30, 2026, before the U.S. market open. The company will host a conference call and webcast at 8:30 AM Eastern Time that day, with a replay archived on its investor website for at least 30 days.
• 1mo ago AI analysis › 84 law-firm class-action alerts